Susan Goode
Family · Foxboro, MANPI 1982755294
Payments from drug & device makers
Across 88 payments — averaging $21.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$357
- Johnson & Johnson$281
- Bayer$175
- Pfizer$166
- Boehringer Ingelheim$157
- AstraZeneca$137
- plus $628 from 13 others
What the payments were for
- Food & beverage$1,900100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 19 | $357 |
| Johnson & Johnson | 11 | $281 |
| Bayer | 8 | $175 |
| Pfizer | 8 | $166 |
| Boehringer Ingelheim | 7 | $157 |
| AstraZeneca(2 entities) | 5 | $137 |
| Mylan Specialty L.p. | 5 | $119 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $100 |
| Merck | 4 | $80 |
| Avanir Pharmaceuticals, Inc. | 4 | $70 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| Lundbeck LLC | 2 | $47 |
| Lilly USA, LLC | 1 | $34 |
| Exact Sciences | 1 | $22 |
| Novartis | 1 | $21 |
| Eisai Inc. | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
How this compares
$1,900 in reported general payments places this provider in the 85th percentile of 2,320 family providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 21 | $34,292 |
| EliquisApixaban | 25 | $28,832 |
| XareltoRivaroxaban | 22 | $25,947 |
| MyrbetriqMirabegron | 13 | $10,422 |
| OzempicSemaglutide | 11 | $10,226 |
| VascepaIcosapent Ethyl | 12 | $4,253 |
| Atorvastatin Calcium | 249 | $3,729 |
| Arnuity ElliptaFluticasone Furoate | 11 | $3,584 |
| Olmesartan Medoxomil | 25 | $2,369 |
| SynthroidLevothyroxine Sodium | 30 | $1,963 |
| Rosuvastatin Calcium | 51 | $1,930 |
| Omeprazole | 110 | $1,718 |
| Valsartan | 30 | $1,651 |
| Levothyroxine Sodium | 137 | $1,447 |
| Metoprolol Succinate | 56 | $1,129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $157 | $34,29221 claims |
| PfizerEliquis | $166 | $28,83225 claims |
| Johnson & JohnsonXarelto | $281 | $25,94722 claims |
| Novo NordiskOzempic | $357 | $10,22611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,320 family providers in Massachusetts.
Other family in Foxboro
- Nicole OuelletteFoxboro$21K
- Paul GouldLakeville$343K
- Brittany MurrayBoston$141K
- Courtney NixonAmherst$81K
- Elizabeth WalshBrighton$80K
- Jennifer FlemingLawrence$80K
- Naomi AmudalaBoston$79K
- Geoffrey WhitleyCharlestown$66K
- Katherine O'BrienWinthrop$58K
- Kristy SmithActon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.